- Home
- RENE vs NBTX Comparison
RENE vs NBTX Comparison
Compare RENE & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENE
- NBTX
- Stock Information
- Founded
- RENE 2021
- NBTX 2003
- Country
- RENE United States
- NBTX France
- Employees
- RENE N/A
- NBTX N/A
- Industry
- RENE Blank Checks
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- RENE Finance
- NBTX Health Care
- Exchange
- RENE Nasdaq
- NBTX Nasdaq
- Market Cap
- RENE 248.9M
- NBTX 201.9M
- IPO Year
- RENE 2022
- NBTX 2020
- Fundamental
- Price
- RENE $11.62
- NBTX $3.83
- Analyst Decision
- RENE
- NBTX Strong Buy
- Analyst Count
- RENE 0
- NBTX 2
- Target Price
- RENE N/A
- NBTX $11.50
- AVG Volume (30 Days)
- RENE 218.7K
- NBTX 8.8K
- Earning Date
- RENE 01-01-0001
- NBTX 11-26-2024
- Dividend Yield
- RENE N/A
- NBTX N/A
- EPS Growth
- RENE 42.92
- NBTX N/A
- EPS
- RENE 0.43
- NBTX N/A
- Revenue
- RENE N/A
- NBTX $45,220,186.00
- Revenue This Year
- RENE N/A
- NBTX N/A
- Revenue Next Year
- RENE N/A
- NBTX N/A
- P/E Ratio
- RENE $26.81
- NBTX N/A
- Revenue Growth
- RENE N/A
- NBTX 526.17
- 52 Week Low
- RENE $10.88
- NBTX $3.57
- 52 Week High
- RENE $11.67
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- RENE 59.82
- NBTX 38.67
- Support Level
- RENE $11.62
- NBTX $3.57
- Resistance Level
- RENE $11.67
- NBTX $4.11
- Average True Range (ATR)
- RENE 0.01
- NBTX 0.28
- MACD
- RENE -0.00
- NBTX -0.00
- Stochastic Oscillator
- RENE 70.59
- NBTX 26.31
About RENE Cartesian Growth Corporation II
Cartesian Growth Corp II is a blank check company.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.